Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts

Treatment of non-small-cell lung cancer (NSCLC) with wild-type epidermal growth factor receptor (EGFR) is still a challenge. This study explored antitumor activity of high-dose icotinib (an EGFR tyrosine kinase inhibitor) plus sequential docetaxel against wild-type EGFR NSCLC cells-generated nude mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Ning, Zhang, Qianqian, Fang, Shu, Han, Xiao, Wang, Zhehai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354720/
https://www.ncbi.nlm.nih.gov/pubmed/27852073
http://dx.doi.org/10.18632/oncotarget.13327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354720/
https://www.ncbi.nlm.nih.gov/pubmed/27852073
http://dx.doi.org/10.18632/oncotarget.13327

Ejemplares similares